| 16.73 0.35 (2.14%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 21.27 | 1-year : | 23.04 |
| Resists | First : | 18.21 | Second : | 19.72 |
| Pivot price | 17.36 |
|||
| Supports | First : | 15.77 | Second : | 13.12 |
| MAs | MA(5) : | 16.54 |
MA(20) : | 17.52 |
| MA(100) : | 16.33 |
MA(250) : | 28.55 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.8 |
D(3) : | 7.4 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 62.75 | Low : | 5.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MLTX ] has closed above bottom band by 29.3%. Bollinger Bands are 19.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 16.88 - 16.96 | 16.96 - 17.03 |
| Low: | 15.86 - 15.96 | 15.96 - 16.04 |
| Close: | 16.57 - 16.73 | 16.73 - 16.87 |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Sat, 02 May 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Fri, 01 May 2026
Short Interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) Decreases By 14.2% - MarketBeat
Thu, 30 Apr 2026
MLTX Price Today: MoonLake Immunotherapeutics Stock Price, Quote & Chart | MEXC - MEXC Exchange
Wed, 29 Apr 2026
MoonLake Immunotherapeutics (MLTX) Proxy Filing Summary - Quartr
Tue, 28 Apr 2026
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Tue, 28 Apr 2026
MLTX Forecast, Price Target & Analyst Ratings | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 10.4 (%) |
| Held by Institutions | 75.6 (%) |
| Shares Short | 7,760 (K) |
| Shares Short P.Month | 7,040 (K) |
| EPS | -3.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -196 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -4.74 |
| PEG Ratio | 0 |
| Price to Book value | 3.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|